agilon health Third Quarter 2026 Earnings Conference - AGILON HEALTH INC

Explicit Guidance:

• Full Year 2026: Increased guidance for revenue to approximately $5.88 billion; medical services expense ratio (MSER) of 90.4%; adjusted EBITDA of approximately $150 million.
• Full Year 2026 Cost Trends: Assumes a cost trend in the 7% range for the remainder of the year.
• Full Year 2026 ACO Reach Adjusted EBITDA: Expected contribution between $40 million and $45 million (including an additional ~$18 million year-to-date contribution from 2025 performance).
• Full Year 2026 Year-End Cash: Expects at least $175 million in cash and marketable securities.
• Full Year 2026 Part D Risk: Reduces exposure from 30% (2025) to approximately 15% (2026), with plans for further reduction in 2027.

Business-Segment Outlook:

• ACO Business (2027): Anticipates membership growth from ~110,000 today to ~160,000 in 2027, driven by MSSP and existing partner expansions; expects material improvement in baseline ACO-adjusted EBITDA performance.
• ACO Membership Mix (2027): Projects a balanced approach between the Medicare Shared Savings Program (MSSP) and other models entering 2027; expects ~40–50% ACO membership growth in 2027, majority via MSSP.
• Clinical Pathways (2027–2028): Will continue expanding CHF, dementia, and lung health pathways; aims to deepen CHF program effectiveness and reduce physician/partner variability; plans to increase virtual pharmacy adoption beyond current ~25% partner participation.
• Payer Contracting (2027): 2027 contracting covers ~50% of book of business; anticipates a "favorable benefit" for 2027 but notes it will be more modest than 2026 due to having already repriced ~80% of membership in the prior year.
• 2028 Growth Strategy: Focuses on evaluating new markets and position groups aligned with the model; new partner onboarding involves a 12- to 18-month implementation timeframe, meaning signings in 2027 will impact 2028.
• Data Coverage: Currently covers ~85% of payers; targets low-to-mid 90s long-term coverage via incremental payer implementations.

Market and Competitive Outlook:

• Quality Performance (Payment Year 2028): Expects 75% of members to be in 4+ star plans (vs. 71% nationally and 77% in 2027).
• Medical Trend Environment: First-half 2026 costs developed favorably (low 6% range); Q3 trends were ~7%; management expects prudent cost trend assumptions for 2027.
• Risk Adjustment: Cited favorable risk adjustment development and higher estimated risk scores as key drivers for 2026 revenue strength; expects continued positive impact from risk adjustment true-ups.
• Value-Based Care Demand: Strong inbound demand from physician groups; high interest from existing and prospective partners for full-risk and MSSP models.

Macro / Industry Outlook:

• Payer Star Recovery: Management expects to participate in upside bonus revenue as payer partners recover Star ratings, provided the recovery is not due to factors outside the management of metrics.
• Regulatory/Industry Models: Confident in flexibility to scale across Medicare Advantage, MSSP, and traditional ACO models within the same organization.

Strategic Initiatives:

• MSSP Expansion: Recently announced three relationship expansions adding nearly 50,000 MSSP members, extending care to traditional Medicare beneficiaries for partners already holding full-risk MA contracts.
• Technology & AI: Investing in AI-enabled capabilities and data infrastructure to reduce administrative burden, drive actionable insights at the point of care, and enhance chronic disease management (specifically CHF, dementia, lung health).
• Operational Execution: Prioritizing reduction of performance variability across the network and strengthening embedded opportunities before pursuing external market expansion.

Risks and Headwinds to Outlook:

• Cost Trend Volatility: Acknowledges limited paid claims visibility for Q3 and potential variability in future cost trends.
• Contracting Economics: Future benefits depend on successful negotiation of remaining 20% of the book of business; future growth is contingent on securing favorable economics and reducing risks outside control.
• Implementation Lag: New market/partner onboarding requires 12–18 months, delaying revenue realization and requiring significant infrastructure/data integration work prior to risk-bearing.
• Risk Adjustment Uncertainty: Outlook is subject to final risk adjustment data and prior year development assumptions.

Management Tone on the Future:

• Confidence Level: High confidence in the 2026 outlook and "durable performance" into 2027 and beyond; described as "encouraged" by ACO business development.
• Strategic Discipline: Emphasizes a "measured approach" to growth, prioritizing embedded opportunities and deepening existing relationships over rapid external expansion.
• Modesty in Growth: Explicitly notes that 2027 contracting benefits will be "more modest" than 2026 due to the prior year's extensive repricing, rather than a negative outlook.

Miscellaneous:

• Investor Event: Virtual event "Driving Performance at Scale, the Agilon Framework" scheduled for November 17th at 2 p.m. ET.
• Q4 Seasonality: Q4 is traditionally the lowest earning quarter; full-year guidance implies a deeper sequential decrease in Q4 medical margin, partly due to the 7% cost trend embedded in the guidance.